Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II — OCCLURANDOM

Pancreatic Neuroendocrine Carcinoma Clinical Trial

Official title:
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II.

Status Recruiting

Clinical Trial Summary

This study is the first randomized, open-label, national, multicenter, phase II study assessing the efficacy and safety of OCLU in subjects with pretreated progressive pancreatic, inoperable, somatostatin receptor positive, well differentiated pancreatic neuroendocrine tumors (WDpNET). Subjects must have experienced documented progression of disease within 1 year prior to the start of the study. The control group of patients receiving Sutent will be used as internal control to assess the hypothesis of 12 months PFS equal to 35% in patients receiving Sutent.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02230176
Study type	Interventional
Source	Gustave Roussy, Cancer Campus, Grand Paris
Contact	Eric BAUDIN, MD, PhD
Phone	0142114244
Email	eric.baudin@gustaveroussy.fr
Status	Recruiting
Phase	Phase 2
Start date	February 2015
Completion date	October 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01365169` - Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"	N/A
Completed	`NCT02101918` - Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery	Phase 2
Completed	`NCT04483349` - Assessment of What Patients and Healthcare Providers Value
Active, not recruiting	`NCT02834013` - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Phase 2
Active, not recruiting	`NCT03884179` - Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy
Active, not recruiting	`NCT02595424` - Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery	Phase 2
Recruiting	`NCT05988918` - Multicenter Trial of ESK981 in Patients With Select Solid Tumors	Phase 2